Showing posts with label numbers. Show all posts
Showing posts with label numbers. Show all posts
Friday, November 18, 2016
WTF???
Labels:
chaos,
cognitive,
deconstruction,
failure,
investment,
macro economy,
masterpiece of the day,
nice idea,
numbers,
real science,
shit of the day,
video
Saturday, October 15, 2016

Labels:
cognitive,
deconstruction,
evidence based medicine,
investment,
macro economy,
nice idea,
numbers,
paradigm
Saturday, July 30, 2016
Friday, April 15, 2016
Where is propaganda???
Labels:
chaos,
cognitive,
deconstruction,
evidence based medicine,
magic,
masterpiece of the day,
nice idea,
numbers,
paradigm,
politics,
video
Thursday, April 14, 2016
Who cares?
Labels:
numbers,
paradigm,
politics,
real science,
video
Saturday, January 2, 2016
ABC of Business strategy
Labels:
chaos,
cognitive,
deconstruction,
future foresight,
masterpiece of the day,
nice idea,
numbers,
paradigm,
video
Saturday, August 29, 2015
How much are you worth?
http://www.washingtonpost.com/news/wonkblog/wp/2015/08/27/cancer-drugs-arent-just-really-expensive-theyre-a-bad-value/
In other Words: $4,200 and $16,700 per month
Or $137 and $548 per day....
Monday, June 29, 2015
Gene therapy - game over!?!
Celladon ($CLDN) is circling the drain, suspending all research tied to its failed gene therapy and again halving its payroll as management searches for a sale and flirts with liquidation.
The San Diego company, which watched its share value evaporate after an April clinical trial failure, is laying off about 50% of its 17-person workforce. Celladon is also halting development of Mydicar, a gene therapy for heart failure that missed its goals in Phase IIb, as well as all of its preclinical programs.
The plan now is to find a merger or sale that can salvage some value, and Celladon has retained Wedbush PacGrow Healthcare to help it find a way forward. If it can't find any takers, the company is prepared to liquidate what assets it has, figuring it can return about $25 million to $30 million in cash to its shareholders.
Celladon was once among the highest profile companies in the gene therapy space, developing a treatment for the common ailment of heart failure in contrast to the rare disease R&D that has largely dominated the field. Mydicar won the FDA's breakthrough-therapy designation last year as the company worked through its Phase IIb study, with management hoping the results might be positive enough to submit to global regulators straightaway.
In the end, Mydicar failed to reduce hospitalizations, improve cardio survival rates or free patients from the need for ventricular-assist devices and heart transplants, an across-the-board failure that decimated the company's market value. Celladon's shares have fallen nearly 90% since the biotech disclosed Mydicar's data, trading at around $1.50.
Earlier this month, CEO Krisztina Zsebo resigned after a decade at Celladon, ceding the reins to former CFO Paul Cleveland as the company began its search for a buyer.
"Our board of directors has unanimously determined that seeking a merger or sale, in lieu of further development of our remaining programs and assets, gives us the best opportunity to maximize shareholder value," Cleveland said in a statement Friday. "We are aggressively pursuing that course."
http://www.fiercebiotech.com/story/celladon-pulls-plug-rd-after-crushing-gene-therapy-failure/2015-06-26?utm_medium=rss&utm_source=feedly&utm_campaign=rss
The San Diego company, which watched its share value evaporate after an April clinical trial failure, is laying off about 50% of its 17-person workforce. Celladon is also halting development of Mydicar, a gene therapy for heart failure that missed its goals in Phase IIb, as well as all of its preclinical programs.
Celladon was once among the highest profile companies in the gene therapy space, developing a treatment for the common ailment of heart failure in contrast to the rare disease R&D that has largely dominated the field. Mydicar won the FDA's breakthrough-therapy designation last year as the company worked through its Phase IIb study, with management hoping the results might be positive enough to submit to global regulators straightaway.
In the end, Mydicar failed to reduce hospitalizations, improve cardio survival rates or free patients from the need for ventricular-assist devices and heart transplants, an across-the-board failure that decimated the company's market value. Celladon's shares have fallen nearly 90% since the biotech disclosed Mydicar's data, trading at around $1.50.
Earlier this month, CEO Krisztina Zsebo resigned after a decade at Celladon, ceding the reins to former CFO Paul Cleveland as the company began its search for a buyer.
"Our board of directors has unanimously determined that seeking a merger or sale, in lieu of further development of our remaining programs and assets, gives us the best opportunity to maximize shareholder value," Cleveland said in a statement Friday. "We are aggressively pursuing that course."
http://www.fiercebiotech.com/story/celladon-pulls-plug-rd-after-crushing-gene-therapy-failure/2015-06-26?utm_medium=rss&utm_source=feedly&utm_campaign=rss
Labels:
bubble,
cognitive,
Death Valley,
deconstruction,
depression,
evidence based medicine,
failure,
future foresight,
investment,
nice idea,
numbers,
paradigm,
real science,
shit of the day,
targeted failure
Thursday, June 18, 2015
Allergan to buy Kythera Biopharmaceuticals in $2.1 billion deal
Labels:
Big Pharma,
bubble,
cognitive,
deconstruction,
investment,
nice idea,
numbers,
paradigm,
real science
Wednesday, June 10, 2015
Yeah...
A trio of insider traders banked about $530,000 on tips from within Ardea Biosciences, according to the SEC, buying shares ahead of major news right up until AstraZeneca ($AZN) bought the company for $1.3 billion.
http://www.fiercebiotech.com/story/sec-insider-traders-lined-their-pockets-astrazenecas-13b-ardea-deal/2015-06-09?utm_medium=rss&utm_source=feedly&utm_campaign=rss
http://www.fiercebiotech.com/story/sec-insider-traders-lined-their-pockets-astrazenecas-13b-ardea-deal/2015-06-09?utm_medium=rss&utm_source=feedly&utm_campaign=rss
Labels:
Big Pharma,
bubble,
cognitive,
deconstruction,
future foresight,
numbers,
paradigm,
real science,
shit of the day
Saturday, May 30, 2015
AstraZeneca and Lilly to test new cancer drug combination
Sweet harmony! Oh-yeahhhh...
http://finance.yahoo.com/news/astrazeneca-lilly-test-cancer-drug-063951294.html
I am disappointed... No other new ideas in drug development?
http://finance.yahoo.com/news/astrazeneca-lilly-test-cancer-drug-063951294.html
Labels:
another magic cure,
Big Pharma,
chaos,
deconstruction,
failure,
numbers,
real science,
shit of the day,
targeted failure
Opdivo - not so good? Targeted failure?
What if mAbs are not Always efficient???
http://www.bloomberg.com/news/articles/2015-05-29/bristol-myers-drug-improves-survival-in-most-common-lung-cancer

http://www.bloomberg.com/news/articles/2015-05-29/bristol-myers-drug-improves-survival-in-most-common-lung-cancer
Labels:
Big Pharma,
bubble,
chaos,
Death Valley,
deconstruction,
failure,
numbers,
paradigm,
shit of the day,
targeted failure
Thursday, May 7, 2015
The magic!
Labels:
chaos,
cognitive,
deconstruction,
future foresight,
masterpiece of the day,
nice idea,
numbers,
politics,
real science
Saturday, May 2, 2015
Let's check in 15 years
Labels:
bubble,
chaos,
cognitive,
deconstruction,
future foresight,
nice idea,
numbers,
politics,
real science
Monday, March 9, 2015
Labels:
another magic cure,
bubble,
cognitive,
deconstruction,
evidence based medicine,
investment,
nice idea,
numbers,
paradigm,
real science,
video
Wednesday, March 4, 2015
Sunday, February 22, 2015
What it means to be 'big pharma' in a $980 billion industry
Labels:
Big Pharma,
bubble,
chaos,
deconstruction,
masterpiece of the day,
nice idea,
numbers,
paradigm,
politics,
real science
Big Pharma Is America’s New Mafia: the communist propaganda
Labels:
Big Pharma,
bubble,
deconstruction,
depression,
evidence based medicine,
future foresight,
macro economy,
numbers,
paradigm,
politics,
real science
Wednesday, February 11, 2015
Marketing to Doctors (HBO)
Labels:
Big Pharma,
bubble,
chaos,
deconstruction,
failure,
future foresight,
nice idea,
numbers,
paradigm,
shit of the day,
video
Friday, January 2, 2015
Fake?
Labels:
chaos,
cognitive,
deconstruction,
depression,
failure,
numbers,
paradigm,
politics,
shit of the day
Subscribe to:
Posts (Atom)
